The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial

Ähnliche Einträge

• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  von: Jochen Seufert, et al.
  Veröffentlicht: (2024)
• The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  von: Ming Liu, et al.
  Veröffentlicht: (2024)
• Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study
  von: Rayaz A. Malik, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: The INITIATION study
  von: Liming Chen, et al.
  Veröffentlicht: (2024)
• Comparable glycemic outcomes with insulin glargine and insulin degludec during exercise in adolescents with type 1 diabetes using a standardized management protocol
  von: Ivana Rabbone, et al.
  Veröffentlicht: (2025)